Declining incidence of contralateral breast cancer in the United States from 1975 to 2006

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1564-1569

  Nichols, Hazel B ^a,b,c   De González, Amy Berrington ^a,b,c   Lacey Jr , James V ^a,b,c   Rosenberg, Philip S ^a,b,c   Anderson, William F ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEER PROGRAM; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79955020033     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.7395     Document Type: Article

References (29)

1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta, GA, American Cancer Society, 2009
2. Snyder CF, Frick KD, Kantsiper ME, et al: Prevention, screening, and surveillance care for breast cancer survivors compared with controls: Changes from 1998 to 2002. J Clin Oncol 27:1054-1061, 2009
3. Snyder CF, Frick KD, Peairs KS, et al: Comparing care for breast cancer survivors to non-cancer controls: A five-year longitudinal study. J Gen Intern Med 24:469-474, 2009
4. De Angelis R, Tavilla A, Verdecchia A, et al: Breast cancer survivors in the United States: Geographic variability and time trends, 2005-2015. Cancer 115:1954-1966, 2009
5. American Cancer Society: Breast Cancer Facts & Figures 2007-2008. Atlanta, GA, American Cancer Society, 2009
6. Curtis RE, Freedman DM, Ron E, et al: New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, 2006
7. Bernstein JL, Lapinski RH, Thakore SS, et al: The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552-558, 2003 (Pubitemid 40417036)
8. Hartman M, Czene K, Reilly M, et al: Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210-4216, 2007 (Pubitemid 47548560)
9. Marshall SF, Ziogas A, Castaneda J, et al: Changing incidence of second primary breast cancer in California. Am J Epidemiol 169:S4, 2009
10. Rosen PP, Groshen S, Kinne DW, et al: Contralateral breast carcinoma: An assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 106:904-910, 1989 (Pubitemid 19283388)
11. Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26:411-414, 2000
12. Vaittinen P, Hemminki K: Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 88:998-1002, 2000
13. Bertelsen L, Mellemkjaer L, Christensen J, et al: Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives. Epidemiology 20:175-180, 2009
14. Fraumeni JF, Curtis RE, Edwards BK, et al: Introduction, New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, 2006
15. Rosenberg PS, Katki H, Swanson CA, et al: Quantifying epidemiologic risk factors using non-parametric regression: Model selection remains the greatest challenge. Stat Med 22:3369-3381, 2003 (Pubitemid 37361339)
16. NATO: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1:257-261, 1983
17. Mariotto A, Feuer EJ, Harlan LC, et al: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 94:1626- 1634, 2002 (Pubitemid 35378728)
18. Anderson WF, Jatoi I, Sherman ME: Qualitative age interactions in breast cancer studies: Mind the gap. J Clin Oncol 27:5308-5311, 2009
19. Healey EA, Cook EF, Orav EJ, et al: Contralateral breast cancer: Clinical characteristics and impact on prognosis. J Clin Oncol 11:1545-1552, 1993 (Pubitemid 23228261)
20. Kurian AW, McClure LA, John EM, et al: Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058-1065, 2009
21. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
22. Jordan VC, Morrow M: Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 95:683-684, 2003; author reply 684-5
23. Svahn TH, Niland JC, Carlson RW, et al: Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. J Natl Compr Canc Netw 7:115-121, 2009
24. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
25. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
26. Ingle JN, Tu D, Pater JL, et al: Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA. 17. Ann Oncol 19:877-882, 2008 (Pubitemid 351627301)
27. Jakesz R, Greil R, Gnant M, et al: Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845- 1853, 2007 (Pubitemid 351767193)
28. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American society of clinical oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
29. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network, 2009